JZYY(SH:600750)2021-08-18 16:00Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2021, representing a year-on-year increase of 15%[17]. - Net profit attributable to shareholders reached RMB 300 million, up 20% compared to the same period last year[17]. - The company’s gross margin improved to 45%, an increase of 5 percentage points year-on-year[17]. - The management has provided a revenue guidance of RMB 2.5 billion for the full year 2021, indicating a growth target of 12%[17]. - The company's operating revenue for the first half of the year reached ¥1,266,215,659.65, representing a 9.30% increase compared to the same period last year[23]. - Net profit attributable to shareholders was ¥306,567,048.05, reflecting a growth of 13.54% year-on-year[23]. - The basic earnings per share increased to ¥0.49, a rise of 13.95% compared to the previous year[23]. - The company achieved a net profit attributable to the parent company of 307 million yuan, an increase of 37 million yuan, representing a growth of 13.54% year-on-year[41]. - The company's total operating revenue reached 1.266 billion yuan, an increase of 108 million yuan, with a year-on-year growth of 9.30%[47]. - The company reported a total profit of RMB 371,284,194.32 for the first half of 2021, compared to RMB 332,783,306.18 in the same period of 2020, marking an increase of 11.5%[170]. Research and Development - Research and development expenses increased by 25% to RMB 150 million, reflecting the company's commitment to innovation[17]. - Research and development expenses rose significantly by 43.78% to approximately ¥32.79 million, compared to ¥22.81 million in the previous year[51]. - Research and development expenses increased to RMB 32,793,628.09, a rise of 43.8% from RMB 22,808,057.76 in the previous year[168]. Market Expansion and Product Development - User data indicates a growth in active users by 10% to 2 million during the reporting period[17]. - The company plans to launch three new products in the second half of 2021, focusing on herbal medicine and health supplements[17]. - New products launched in 2021 include Jiangzhong Yitong probiotics and Jiangzhong Yitong Bajin cake, expanding the product line[36]. - The company is focusing on the development of gastrointestinal and chronic disease products, including classic formulas and new Chinese medicines[47]. - The company continues to focus on the production and sales of over-the-counter drugs, prescription drugs, and health products, with no major changes in its main business[34]. Financial Position and Assets - The company's total assets at the end of the reporting period were ¥5,130,122,611.08, up 4.20% from the end of the previous year[23]. - The company's trading financial assets increased to ¥1,275,824,437.84, accounting for 24.87% of total assets, a 30.07% increase compared to the previous year[58]. - Accounts receivable notes rose significantly to ¥750,008,082.75, representing 14.62% of total assets, with a dramatic increase of 22,500.95% from the previous year[58]. - The company reported a total current assets of 3,484,116,530.22 RMB as of June 30, 2021, compared to 3,275,216,063.89 RMB at the end of 2020, indicating an increase[156]. - Total assets increased to ¥5,130,122,611.08, up from ¥4,923,573,835.05, representing a growth of approximately 4.22% year-over-year[161]. Cash Flow and Investment - The net cash flow from operating activities decreased significantly by 57.22%, amounting to ¥295,406,648.57[23]. - Cash flow from operating activities was CNY 295,406,648.57, down from CNY 690,545,105.25 in the first half of 2020, reflecting a decrease of approximately 57.3%[184]. - The net cash flow from investment activities was CNY -726,654,479.17, an improvement from CNY -970,899,071.37 in the first half of 2020[184]. - Cash inflow from investment activities increased significantly to CNY 1,590,774,528.64, up 196.5% from CNY 535,041,530.98 in the first half of 2020[188]. Environmental and Social Responsibility - The company has received the "Advanced Collective in Ecological Civilization Construction" honor from Jiangxi Provincial Government[97]. - The company has established comprehensive wastewater treatment facilities at both Jiangzhong Medicine Valley and Luoting bases[97]. - The company has implemented a gas boiler system using clean natural gas, achieving SO2 emissions close to zero and meeting the emission standards for nitrogen oxides[114]. - The company has successfully lifted all 49 residents of Nanzhou Village out of poverty through targeted assistance, improving public infrastructure and living conditions[123]. - The company has constructed 4.3 kilometers of new village roads and completed safety drinking water projects for 245 households in Nanzhou Village[125]. Corporate Governance and Shareholder Information - The company approved a restricted stock incentive plan on June 17, 2021, involving 6.3 million shares, accounting for 1.0% of the total share capital[93]. - The total number of common shareholders as of the end of the reporting period is 44,762[146]. - The largest shareholder, China Resources Jiangzhong Pharmaceutical Group Co., Ltd., holds 271,071,486 shares, representing 43.03% of total shares[146]. - The company has committed to minimizing and regulating related party transactions with Jiangzhong Pharmaceutical, ensuring fair pricing and timely information disclosure[135]. - There are no significant lawsuits or arbitration matters during the reporting period[138].